Lineage Cell Therapeutics Inc LCTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LCTX is a good fit for your portfolio.
News
-
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
-
Lineage to Present at 2024 BIO International Convention
-
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
-
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
-
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
-
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
-
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
-
Lineage Announces Changes to Board of Directors
Trading Information
- Previous Close Price
- $1.04
- Day Range
- $1.00–1.08
- 52-Week Range
- $0.84–1.61
- Bid/Ask
- $1.01 / $1.05
- Market Cap
- $192.60 Mil
- Volume/Avg
- 615,172 / 964,060
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.41
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 75
- Website
- https://www.lineagecell.com
Comparables
Valuation
|
Metric
|
LCTX
|
NRIX
|
BLUE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.66 | 3.80 | 0.59 |
Price/Sales | 22.41 | 19.90 | 5.70 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LCTX
|
NRIX
|
BLUE
|
|---|---|---|---|
Quick Ratio | 2.59 | 5.49 | 1.24 |
Current Ratio | 2.71 | 5.57 | 1.55 |
Interest Coverage | — | — | — |
Quick Ratio
LCTX
NRIX
BLUE
Profitability
|
Metric
|
LCTX
|
NRIX
|
BLUE
|
|---|---|---|---|
Return on Assets (Normalized) | −16.79% | −37.66% | −12.29% |
Return on Equity (Normalized) | −26.16% | −56.12% | −30.63% |
Return on Invested Capital (Normalized) | −27.84% | −55.89% | −15.27% |
Return on Assets
LCTX
NRIX
BLUE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Xygrpdprb | Mzcrv | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dcqzbvbh | Cnqbhp | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nwhwcswg | Pnhjxmf | $118.7 Bil | |||
| Moderna Inc
MRNA
| Kmcrtprp | Wpln | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Btpzclh | Bpxhr | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Tdlyjlvq | Myqk | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Wkxbqtj | Phqq | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xlznxvlj | Byqpkr | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rqfdwvn | Mssfc | $15.0 Bil | |||
| Incyte Corp
INCY
| Cskxxlzm | Klskxt | $13.5 Bil |